Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Vadovics M, Zhao W, Daley EF, Lam K, Daly O, Rashid K, Lee HR, Schreiner P, Lundgreen KA, Gaudette BT, Shuvaev VV, Arguiri E, Muramatsu H, S?rk?zy A, Mdluli T, Xu J, Han X, De Luna N, Casta?o D, Bettini E, ?brah?m E, Lipinszki Z, Carlucci G, Bansode AH, Nguyen K, Le TM, Luu T, Muzykantov VR, Bates P, Allman D, Mitchell MJ, Locci M, Radu CG, Heyes J, Pardi N. Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications. Nat Nanotechnol. 2025 Sep; 20(9):1312-1322.
-
Wang R, Oliveira LVN, Hester MM, Carlson D, Christensen D, Specht CA, Levitz SM. Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines. PLoS Pathog. 2024 Jul; 20(7):e1012220.
-
Alsaiari SK, Nadeef S, Daristotle JL, Rothwell W, Du B, Garcia J, Zhang L, Sarmadi M, Forster TA, Menon N, Lin SQ, Tostanoski LH, Hachmann N, Wang EY, Ventura JD, Barouch DH, Langer R, Jaklenec A. Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer. Sci Adv. 2024 03 08; 10(10):eadj6380.
-
Marques RF, Gimenez AM, Caballero O, Simpson A, Salazar AM, Amino R, Godin S, Gazzinelli RT, Soares IS. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol?) as adjuvant. Vaccine. 2024 04 02; 42(9):2394-2406.
-
Dias Assis BR, Gomes IP, de Castro JT, Rivelli GG, de Castro NS, Gomez-Mendoza DP, Bagno FF, Hojo-Souza NS, Chaves Maia AL, Lages EB, da Fonseca FG, Ribeiro Teixeira SM, Fernandes AP, Gazzinelli RT, Castro Goulart GA. Quality attributes of CTVad1, a nanoemulsified adjuvant for phase I clinical trial of SpiN COVID-19 vaccine. Nanomedicine (Lond). 2023 08; 18(18):1175-1194.
-
Han X, Alameh MG, Butowska K, Knox JJ, Lundgreen K, Ghattas M, Gong N, Xue L, Xu Y, Lavertu M, Bates P, Xu J, Nie G, Zhong Y, Weissman D, Mitchell MJ. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat Nanotechnol. 2023 09; 18(9):1105-1114.
-
Tran CA, Lynch KT, Meneveau MO, Katyal P, Olson WC, Slingluff CL. Intratumoral IFN-? or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine. J Immunother Cancer. 2023 02; 11(2).
-
Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley H, Morris A, Mauro D, Wooldridge JE, Luke JJ, Weiner GJ, Krieg AM, Milhem MM. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
-
Chase Huizar C, Ji N, Reddick R, Ostroff GR, Forsthuber TG. Glucan particles as a novel adjuvant for the induction of experimental autoimmune encephalomyelitis. Cell Immunol. 2021 08; 366:104383.
-
Dos Santos Dias L, Dobson HE, Bakke BK, Kujoth GC, Huang J, Kohn EM, Taira CL, Wang H, Supekar NT, Fites JS, Gates D, Gomez CL, Specht CA, Levitz SM, Azadi P, Li L, Suresh M, Klein BS, W?thrich M. Structural basis of Blastomyces Endoglucanase-2 adjuvancy in anti-fungal and -viral immunity. PLoS Pathog. 2021 03; 17(3):e1009324.